Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Brodalumab effectively treated a man's severe hand and foot psoriasis.

In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.

This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.

In this study, researchers found that patients with psoriasis had a higher probability of achieving and maintaining a clinical response using brodalumab compared to ustekinumab over 52 weeks, as measured by a multistate modelling approach based on absolute PASI scores.

This study found that using a method based on absolute PASI, patients with psoriasis receiving brodalumab had a higher probability of achieving and maintaining a treatment response over 52 weeks compared to those receiving ustekinumab.

This report describes two cases where patients developed alopecia while undergoing treatment for psoriasis with IL-17 inhibitors, suggesting an unexpected paradoxical reaction.

Adalimumab improved folliculitis decalvans in most patients.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.

This case report from the provided study details a previously unreported adverse effect of salivary gland inflammation potentially linked to acitretin therapy for generalized pustular psoriasis, suggesting further research is needed to explore this association.

This study found that administering dupilumab to patients with moderate-to-severe atopic dermatitis over 12 weeks altered both fungal and bacterial skin microbiomes, increasing microbial diversity and decreasing colonization by Malassezia and Staphylococcus aureus at lesion sites.

This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This review discusses the roles of αβ and γδ T cells in skin health and disease and reports no new clinical results; the authors highlight potential therapeutic developments.

This review summarizes 15 years of clinical and experimental research advancements in hidradenitis suppurativa, highlighting its recognition as a uniquely healable inflammatory skin disease but reports no new clinical results.

This article reviews the role of perifollicular regulatory T cells in maintaining hair follicle integrity in the context of hidradenitis suppurativa and calls attention to inflammatory mechanisms without reporting new clinical results.

This review discusses the complex causes and treatment challenges of chronic inflammatory skin diseases, emphasizing the need for biomarkers to predict treatment responses; it reports no new clinical results.

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

This study observed that patients with alopecia areata often have comorbidities and experience significant healthcare costs, with treatments like systemic therapies being infrequently used.

This review explores the autoimmune hypothesis of alopecia areata and the possible genetic and melanogenesis-associated autoantigens, but reports no new clinical findings.

In this scoping review, researchers found that while some dietary approaches may help improve psoriasis symptoms—particularly in those with obesity or coeliac disease—the overall evidence is limited, and larger studies are necessary to identify effective diets for the broader psoriasis population.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

This case report describes a 37-year-old woman who developed scalp psoriasis and severe alopecia after taking adalimumab, with complete hair regrowth following treatment change.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This chapter reviews recent developments in vitiligo research, highlighting the role of melanocyte stem cell differentiation and oxidative stress in its management, but reports no new clinical results.

This study reviews current systemic treatments for hidradenitis suppurativa, highlighting traditional methods and new options like biological agents, and suggests that pharmacological therapies show promise, particularly for non-advanced cases, despite the disease's complex etiology involving factors such as genetics and inflammation.

This source provides medical information intended solely for licensed professionals and emphasizes that it is not a substitute for medical advice, diagnosis, or treatment decisions, which remain the responsibility of treating physicians.